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Abstract UBC9 protein (E2-conjugating enzyme) plays a
key role in post-translation modification named sumoylation.
Proteins, which are sumoylated take part in many cellular
processes including cell growth, maintaining the genome in-
tegrity and stability and cancer development. The aim of this
study was to investigate an association between three poly-
morphisms of the UBC9 gene: c.73G>A (rs11553473),
c.430T>G (rs75020906) and g.1289209T>C (rs7187167)
and a risk of ductal breast cancer occurrence. We performed
a case-control study in 181 breast cancer cases and 277 controls
using PCR-RLFP and ASO-PCR. In the case of the 430T>G
polymorphism of the UBC9 gene lack of variability suggests
that there is not a polymorphic site in polish population. We
observed that a risk of breast cancer occurrence is elevated in
patients with the G/A genotype (OR 5.03; 95 % Cl 3.05–8.28),
the A/A genotype (OR 11.3; 95 % Cl 4.24–30.3) and the A
allele (OR 6.86; 95 % Cl 4.43–10.6) of the c.73G>A polymor-
phism. In the case of the g.1289209T>C polymorphism we
found a correlation between estrogen receptor (ER) expression
and the T/T genotype (OR 0.22; 95 % Cl 0.07–0.64) and the T
allele (OR 0.53; 95 % Cl 0.32–0.88). We also found a correla-
tion between the T/T genotype (OR 4.13; 95 % Cl 1.21–14.1)
and the T allele (OR 2.09; 95 % Cl 1.07–4.08) of the
g.1289209T>C polymorphism with triple negative breast can-
cer. Our results suggest that the variability of the UBC9 gene
can play a role in breast cancer occurrence.
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Introduction
Small ubiquitin-related modifier (SUMO-1, 2 and 3) conju-
gation is a type of post-translational modification of proteins
named sumoylation. Sumoylation is the process that requires
few steps of enzymatic reactions, like maturation, activation,
conjugation and ligation. Mature SUMO protein is activated
by the heterodimeric SUMO E1 enzyme (SAE1/SAE2).
Next, SUMO protein is displaced from the E1 complex to
the E2 conjugating enzyme named UBC9. The enzyme cat-
alyzes the formation of izopeptide bond between the C-
terminal Gly residue of SUMO protein and ɛ-amino group
of Lys residue in the target protein. In the last step SUMO
protein is attached to its substrate. This step can occur on two
ways: directly by E2 or by the E3 enzyme [1]. Sumoylation is
similar to ubiquitination, but the biological functions of these
two processes can be quite distinct. Unlike ubiquitination that
normally targets proteins for degradation through proteasome
pathway, sumoylation regulates divers cellular processes, in-
cluding DNA replication and repair, chromosome packing and
dynamics, genome integrity, nuclear transport, signal trans-
duction and cell proliferation [2].
UBC9 is the only known E2 conjugating enzyme that
exists for sumoylation. It exerts a central function for the
sumoylation pathway, interacting with almost all the partners
required for sumoylation. In addition, recent evidences indi-
cate that UBC9 is a multifunctional protein that can exert its
functions independent of sumoylation [3, 4]. It is over-
expressed in several cancers like colon, prostate, breast,
lung, ovarian, melanomas, head and neck [5–7]. Wu et al.
[8] reported that in breast cancer the UBC9 level was >5-fold
higher than the matched normal tissues. UBC9 has also been
shown to bind to HMG1 proteins and integrate both positive
and negative signals for proliferation and transformation [9].
Recently UBC9 was found to promote cell invasion and
metastasis of breast cancer cells [4], implicating a role in
tumorigenesis.
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SUMO modification can influence a plethora of transcrip-
tion factors and co-factors. Sumoylation of transcription fac-
tors can lead to transcriptional activation but has been mostly
associated with transcriptional repression. Attenuation or re-
pression of their transcriptional activity has been observed for
the majority of nuclear receptors like ER (estrogen receptor),
PR (progesterone receptor) and AR (androgen receptor)
[10–12].
The SUMO modification pathway was also shown to be
involved in response to DNA damage [13, 14]. Number of
studies suggests a link between repair of DNA, especially
DNA double strand breaks (DSBs) and genetics predisposi-
tion to hereditary as well as sporadic breast cancer [15–18].
Known breast cancer susceptibility genes like BRCA1,
BRCA2, ATM, CHK2, TP53 are involved in the repair of
DSBs and related processes such as cell cycle control, indi-
cating that disturbances of DNA DSBs repair might result in
breast cancer development.
UBC9 protein, the key enzyme of sumoylation, may
take part in breast cancer development resulting in a
change of localization, activity and stability of modified
proteins. For this reason, UBC9 may also serve as a
potential biomarker for diagnosis or prognosis as well
as a therapeutic target for breast cancer therapy. Genetic
variability may affect expression and activity of UBC9
gene or/and protein and may have an impact on breast
cancer occurrence and progression.
In the present study, we investigated a correlation between
three polymorphic variants (SNPs) of theUBC9 gene (c.73G>A
rs11553473, c.430T>G rs75020906, g.1289209T>C rs7187167)
and breast cancer risk. We also studied an association between
the above polymorphisms of the UBC9 gene and clinical char-
acteristics of breast cancer patients such as tumor grade, tumor
stage and ER and PR (estrogen and progesterone receptors,
respectively) and HER2 expression (human epidermal growth
factor 2).
Patients, Materials and Methods
Patients
Blood samples were collected from 181 women (mean
age 60±11 years) diagnosed with ductal breast cancer
treated at the Department of Surgical Oncology, N.
Copernicus Hospital (Lodz, Poland). Blood was collect-
ed before surgical treatment and chemotherapy. The con-
trol group consisting of 277 women is age-matched women
who were not diagnosed with cancer and recruited from
Commune Health Clinic in Rzgow and Institute Polish
Mother’s Health Center (Lodz, Poland). The Local Ethic
Committee approved the study and each patient gave a written
consent.
Genomic DNA Isolation
Genomic DNAwas prepared from peripheral blood of breast
cancer patients and healthy individuals by using of commer-
cial Blood Genomic DNA Miniprep Kit (Axygen Biosci-
ences, CA, USA), as recommended by the manufacturer.
Selection of Polymorphisms and Primers Design
We obtained a list of SNPs in the UBC9 gene from the public
domain of the National Center for Biotechnology Informa-
tion–the Single Nucleotide Polymorphisms database (NCBI
dbSNP) at http://www.ncbi.nlm.nih.gov/snp. For this studywe
chose the three polymorphisms of the UBC9 gene: c.73G>A
(rs11553473), c.430T>G (rs75020906) and g.1289209T>C
(rs7187167) with minor allele frequency higher than the 1 %.
Primers were designed using Primer–Blast software (http://
www.ncbi.nlm.nih.gov/tools/primer-blast/) and Web-based
allele-specific primer software in the case of the c.73G>A
(rs11553473) (http://bioinfo.biotec.or.th/WASP).
Genotype Determination
The restriction fragment length polymorphism reaction (PCR-
RFLP) was used to determine the genotypes of the c.430T>G
and the g.1289209T>C polymorphisms of the UBC9 gene.
The allele-specific polymerase chain reaction (ASO-PCR)
was used to determine the genotypes of the c.73G>A poly-
morphism of the UBC9 gene.
PCR reaction was performed in a total reaction volume of
25 μl containing 50 ng of genomic DNA, 1 U Biotools DNA
polymerase (Biotools, Madrid, Spain), 1×reaction buffer
(750 mM Tris–HCl (pH 9.0), 500 mM KCl, 200 mM
(NH4)2SO4), 1.5 mM MgCl2, 0.2 mM of each dNTP and
0.25 μM of each primer (Metabion, Martinsried, Germany
and SIGMA-ALDRICH Co. St. Louis, MO, USA). PCR
amplifications were conducted in DNA Engine thermal cy-
cler (Bio-Rad Laboratories, Hercules, CA, USA). Thermal
cycling conditions were as follows: initial denaturation step
at 95 °C for 5 min, 34 cycles at 95 °C for 30 s, 30 s at 63 °C,
63.5 °C and 76 °C annealing temperature for c.73G>A,
c.430T>G and g.1289209T>C polymorphisms respectively,
elongation step at 72 °C for 60 s and final elongation step at
72 °C for 5 min.
The products of the c.430T>G polymorphism of theUBC9
gene were digested 1 h with 0.2 U of the restriction enzyme
RsaI and the products of the g.1289209T>C polymorphism of
the UBC9 gene were digested 2 h with 0.2 U of the restriction
enzyme BsaHI (NEB New England Biolabs, Ipswich, MA,
USA). The PCR products of the g.1289209T>C and the
c.430T>G polymorphisms were separated into 10 % polyacryl-
amide gel and the PCR products of the c.73G>A polymorphism
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were separated onto 3 % agarose gel, stained with ethidium
bromide and viewed under UV light.
Statistical Analysis
Statistical analysis was performed using Sigma Plot 11.0 statis-
tical package. A linkage between genotype, cancer and clinical
parameters was accessed by the logistic regression. In all tests p
values of less than 0.05 were considered statistically significant.
Results
Genotype Analysis
Breast cancer patients and controls were divided into groups
corresponding to three genotypes. In the case of the c.430T>G
polymorphism of the UBC9 gene we observed only the T/T
genotype. Therefore, above place cannot be treated as a poly-
morphic site (data not shown). The distribution of genotypes of
the c.73G>A and the g.1289209T>C polymorphisms of the
UBC9 gene for cancer patients and controls is shown in Table 1.
We observed a strong association between breast cancer
occurrence and the G/A genotype (OR 5.03; 95 % Cl 3.05–
8.28), A/A genotype (OR 11.3; 95%Cl 4.24–30.3) and A allele
(OR 6.86; 95%Cl 4.43–10.6) of the c.73G>Apolymorphism of
the UBC9 gene. We also observed a strong correlation between
cancer and combination of genotypes: GA/CC, AA/CC and
AA/CT. Protective effect was observed for combination of
GG/CT genotypes of the c.73G>A and g.1289209T>C
polymorphisms.
There was no difference in the frequency of the genotypes
and alleles of the g.1289209T>C polymorphism of the
UBC9 gene between patients and controls.
Hormone Receptor Status
We checked the distribution of genotypes and alleles of the
UBC9 gene polymorphisms in groups of patients with differ-
ent hormone receptor status. An association between estrogen
hormone receptor status and the T/T genotype (OR 0.22; 95%
Cl 0.07–0.64) and T allele (OR 0.53; 95 % Cl 0.32–0.88) of
the g.1289209T>C polymorphism of the UBC9 gene was
found (Table 2). We did not observe any association between
estrogen hormone receptor status and the distribution of ge-
notypes and alleles for the c.73G>A polymorphism of the
Table 1 The genotype and allele
distribution and odds ratios (OR)
of the g.1289209T>C and the
c.73G>A polymorphisms of the
UBC9 gene in breast cancer pa-
tients and controls










C/C 85 120 1.00 ref.
C/T 80 148 0.90 0.58–1.38 0.615
T/T 16 7 2.58 1.00–6.65 0.050
C 250 388 1.00 ref.
T 112 162 1.24 0.87–1.77 0.232
c.73G>A
G/G 52 228 1.00 ref.
G/A 89 40 5.03 3.05–8.28 <0.001
A/A 40 7 11.3 4.24–30.3 <0.001
G 193 496 1.00 ref.
A 169 54 6.86 4.43–10.6 <0.001
c.73G>A/g.1289209T>C
GG/CC 22 102 1.00 ref.
GG/CT 25 119 0.116 0.063–0.211 <0.001
GG/TT 5 7 0.471 0.135–1.639 0.236
GA/CC 41 15 3.456 1.64–7.283 0.001
GA/CT 41 25 1.439 0.771–2.689 0.253
GA/TT 7 0 5.704 0.671–48.488 0.111
AA/CC 22 3 5.227 1.464–18.667 0.011
AA/CT 14 4 7.47 1.58–35.31 0.011
AA/TT 4 0 4.686 0.391–56.184 0.223
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UBC9 gene (data not shown). We did not observe any asso-
ciation between progesterone hormone receptor status, HER2
expression and the distribution of genotypes and alleles for
analyzed polymorphisms of the UBC9 gene (data not shown).
We found a correlation between the T/T (OR 4.13; 95 % Cl
1.21–14.1) and T allele (OR 2.09; 95 % Cl 1.07–4.08) of the
g.1289209T>C polymorphism of the UBC9 gene and the
triple negative breast cancer (Table 3).
Clinical-Histopathological Parameters
We checked the distribution of genotypes and alleles of the
UBC9 gene polymorphisms for breast cancer patients strat-
ified by Bloom-Richardson grading system and TNM stag-
ing. We did not find any association between the c.73G>A
and the g.1289209T>C polymorphisms of the UBC9 gene
and Bloom-Richardson tumor grade and TNM stage (data
not shown).
Discussion
In this study, we analyzed an association of the three poly-
morphisms of the UBC9 gene: c.73G>A (rs11553473),
c.430T>G (rs75020906) and g.1289209T>C (rs7187167)
with a risk of ductal breast cancer occurrence. We observed
a strong association between breast cancer occurrence and
the G/A and A/A genotypes and the A allele of the c.73G>A
polymorphism (Table 1). These genotypes and the A allele
increased a risk of breast cancer occurrence. Moreover, we
found that the some genotype combinations of the
g.1289209T>C and c.73G>A polymorphisms correlated
with breast cancer risk (Table 1). We have not noted variation
in the frequency of genotypes associated with the c.430T>G
(rs75020906)-UBC9 gene polymorphism (data not shown).
The most interesting results we obtained by analyze the
g.1289209T>C polymorphism and receptors status. We
found that the variant allele was inversely related to ER
Table 2 The genotype and allele
distribution and odds ratios (OR)
of the g.1289209T>C and
c.73G>A polymorphisms of the
UBC9 gene in groups of patients
with different estrogen receptor
status




OR OR (95 % Cl) P value
g.1289209T>C
C/C 62 21 1.00 ref.
C/T 51 22 1.07 0.55–2.08 0.852
T/T 6 10 0.22 0.07–0.64 0.006
C 175 64 1.00 ref.
T 63 42 0.53 0.32–0.88 0.014
c.73G>A
GG 35 14 1.00 ref.
GA 58 27 0.90 0.47–1.74 0.757
AA 26 12 0.95 0.43–2.09 0.903
G 128 55 1.00 ref.
A 110 51 0.95 0.43–2.09 0.903
Table 3 The genotype and allele
distribution and odds ratios (OR)
of the g.1289209T>C and
c.73G>A polymorphisms of the
UBC9 gene for triple negative
breast cancer patients
Triple negative–ER, PR and
HER2 negative breast cancer
patients
Others–at last one receptor posi-
tive breast cancer patients (ER or
PR or HER2 positive)




OR OR (95 % Cl) P value
g.1289209T>C
C/C 8 72 1.00 ref.
C/T 11 60 1.07 0.43–2.63 0.886
T/T 5 10 4.13 1.21–14.1 0.024
C 27 204 1.00 ref.
T 21 80 2.09 1.07–4.08 0.030
c.73G>A
GG 8 40 1.00 ref.
GA 11 71 0.89 0.37–2.17 0.796
AA 5 31 0.96 0.33–2.85 0.944
G 27 151 1.00 ref.
A 21 133 0.92 0.49–1.72 0.793
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positive breast cancer (Table 2). What is more, we observed
that the T/T genotype and the T allele positively correlated
with phenotype of triple negative breast cancer (Table 3).
This is a subtype of breast cancer characterizing by the lack
of expression of ER, PR and HER2 and by this way is called
a triple negative breast cancer (TNBC). This subgroup ac-
counts for about 15 % of all breast cancers and for a higher
percentage of breast cancers detected in African and African-
American women who are premenopausal [19]. TNBC has
important clinical implications, because it is typicality high
grade, has a ductal histology and exhibits a high rate of
proliferation. In general, compared with other subtypes of
breast cancer, TNBC has a less favorable clinical outcome in
terms of the nature and likelihood of progression, availability
of various treatment options, and survival [20–22].
TNBC tumors are strongly associated with germline mu-
tations in the BRCA1 gene [20–22]. In sporadic breast can-
cer, BRCA1 mutations are rare, but reduced expression or
aberrant subcellular localization of BRCA1 is common
among young African-American women with TNBC [19].
BRCA1 is a tumor suppressor that undergoes active nuclear
import and export, which can provide a regulatory function.
Moreover, BRCA1 is a key mediator of DNA repair path-
ways, especially of DNADSBs repair, and participates in the
maintenance of the genomic integrity of cells [22]. The
nuclear-cytoplasm shuttling of BRCA1 may offer an impor-
tant mechanism for regulating its function. Nuclear transport
of proteins can be altered either by mutations or through
post-translational modifications include phosphorylation,
ubiquitylation, glycosylation and sumoylation within or
proximal to nuclear import/export signals which could cause
a conformational change, thus preventing the binding of
proteins like UBC9 resulting in non-nuclear distribution of
BRCA1 proteins [19]. The results obtained by Qin et al. [19]
and previously by Xu et al. [23] are consistent with the model
that a direct interaction of BRCA1 with UBC9 is critical for
growth-tumor suppression by BRCA1 and ER-α levels caus-
ing transformation. These results suggest a molecular inter-
play between BRCA1 and UBC9, which maintains the bal-
ance of two opposing effects: tumor suppression (inhibition
of ER-α) or tumorigenesis (activating ER-α). BRCA1 dys-
function can tilt this delicate balance resulting in ER-α
positive or ER-α negative breast cancer. BRCA1 thus func-
tions as a master switch, which by turning off or on UBC9
binding regulates ER-α transcription and cell growth. This
model explains how BRCA1 can both activate and repress
ER-α transcription in hormone responsive tissues like breast
and ovarian. Post-translational modification of BRCA1 pro-
teins could prevent the binding of BRCA1 to UBC9 resulting
in breast cancers [19].
There is little data on the genetic variation of the UBC9
gene, its impact on the function of UBC9 protein and poten-
tial role in the development of breast cancer [24–26].
Previously, we showed that breast cancer patients with var-
iant allele of the c.73G>A polymorphism of the UBC9 gene
(rs11553473) have decreased efficacy of DNA DSBs repair
[26]. Further studies are needed to clarify the mechanism of
DNA DSBs repair reduction observed in carriers of the
variant allele.
In summary, our data suggest that genetic variants of the
UBC9 gene, c.73G>A (rs11553473) and g.1289209T>C
(rs7187167), may play role in the development of breast cancer.
Probably, these polymorphic variants cannot be considered as
independent markers, but rather the elements of a set of breast
cancer markers. Further studies are needed to clarify their
biological functions during breast cancer development.
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